Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Azaya Therapeutics Patents Nanotherapy Breakthrough

Abstract:
Drugs Coming Off Patent Could Get New Life From PSL™ Technology Platform

Azaya Therapeutics Patents Nanotherapy Breakthrough

SAN ANTONIO, TX | Posted on March 12th, 2007

Azaya Therapeutics, Inc., a company developing technology for targeted, safer and more effective chemotherapy drugs, has been granted a patent from the U.S. Patent and Trademark Office for Azaya's novel PSL nanotechnology platform. The PSL technology allows for the consistent loading, sizing and stabilizing of active drugs into targeted nanoparticles.

The company's first application of its PSL technology is an innovative, targeted and more efficacious formulation of one of the world's top-selling chemotherapy drugs. Oncology drugs are a $60+ billion annual worldwide market with a growth rate forecast of 16 percent annually. With some of the top-selling oncology drugs coming off patent over the next several years, PSL technology has the potential to extend the life of many of these drugs for years with formulations that make them more effective than their original versions, said Azaya president and CEO Michael T. Dwyer.

"PSL nanotechnology is a breakthrough for the formulation and targeting of effective, yet insoluble drugs and has the potential for very broad application to a wide variety of formulations," said Dwyer. "We have been able to demonstrate that PSL formulation of a standard-of-care, yet toxic, chemotherapeutic allows for dosing at higher levels, increased drug concentration and circulation time, and statistically significant tumor growth inhibition compared to the original formulation. We've clearly proven the principle of what PSL nanoparticles are capable of doing."

Drugs for diseases other than cancer may offer similar opportunities, Dwyer said.

####

About Azaya Therapeutics
Azaya’s one-step, proprietary manufacturing process allows for the consistent production of uniform nanoparticles. This size allows for selective tumor accumulation due to the tumor’s leaky vasculature. PSLs also offer significant advantages in stabilization and loading efficiency compared to products from competing companies.

With the securing of Azaya’s patent protection in this area, the company will be presenting the results of pre-clinical studies involving PSLs at the April 2007 meeting of the American Association of Cancer Researchers. Additionally, the company expects to begin a phase I clinical trial of their lead candidate later this year.

Azaya’s business strategy, built around the PSL nanotechnology platform, focuses on three main areas: reformulating existing drugs, licensing PSL nanotechnology to third-party biopharmaceutical companies and developing new PSL-based drugs using promising compounds Azaya has identified.

The company’s management is highly experienced in biotechnology and oncology and has a track record of obtaining FDA drug approvals and successfully building companies. Dwyer previously held several key executive positions with Ilex Oncology, Inc. and was instrumental in the development and approval of the company’s drug, Campath® (alemtuzumab).

For more information, please click here

Contacts:
Azaya Therapeutics, Inc., San Antonio
Michael T. Dwyer, 210-341-6600
or
Dublin & Associates
Eric Whittington, 210-227-0221, ext. 239

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Spinning strands hint at folding dynamics: Rice University lab uses magnetic beads to model microscopic proteins, polymers October 17th, 2017

Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting(R) October 10th, 2017

Arrowhead to Present at Chardan Gene Therapy Conference October 3rd, 2017

'CRISPR-Gold' fixes Duchenne muscular dystrophy mutation in mice October 3rd, 2017

Announcements

Creation of coherent states in molecules by incoherent electrons October 21st, 2017

Novel 'converter' heralds breakthrough in ultra-fast data processing at nanoscale: Invention bagged four patents and could potentially make microprocessor chips work 1,000 times faster October 20th, 2017

Strange but true: turning a material upside down can sometimes make it softer October 20th, 2017

Leti Coordinating Project to Develop Innovative Drivetrains for 3rd-generation Electric Vehicles: CEA Tech’s Contribution Includes Liten’s Knowhow in Magnetic Materials and Simulation And Leti’s Expertise in Wide-bandgap Semiconductors October 20th, 2017

Patents/IP/Tech Transfer/Licensing

Novel 'converter' heralds breakthrough in ultra-fast data processing at nanoscale: Invention bagged four patents and could potentially make microprocessor chips work 1,000 times faster October 20th, 2017

Nanoparticles limit damage in spinal cord injury: Injection after an injury reduces inflammation and scarring September 6th, 2017

More durable, less expensive fuel cells: University of Delaware researchers have developed a new technology that could speed up the commercialization of fuel cell vehicles September 5th, 2017

Argonne National Laboratory’s Continuous ALD Technology Licensed Exclusively to Forge Nano July 7th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project